Uveitis Market Is Poised To Grow At A Decent CAGR By 2034, Estimates Delveinsight

Some facts of the Uveitis Market Report are:

• In October 2025, Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA® (adalimumab-aaty) and its unbranded version, to include the treatment of hidradenitis suppurativa (HS) in adolescent patients aged 12 years and older, and uveitis (UV) in pediatric patients aged 2 years and older.
• In June 2025, AbbVie announced a study is to assess adverse events and effectiveness of adalimumab in Chinese participants requiring high-dose corticosteroids with NIIPPU. Adalimumab is a conditionally approved drug in China used to treat participants with NIIPPU. All participants will receive the same treatment. Approximately 87 adult participants will be enrolled at approximately 15 sites in China.
• In March 2025, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The approval also includes other updates to the label including to the Warnings and Precautions section. As previously announced, the Company plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S. ILUVIEN is already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.
• The total uveitis market size of in the 7MM was approximately USD 1,468 million in 2022 and is projected to increase during the forecast period (2023-2034).
• As per DelveInsight analysis, in 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM.
• The total number of Uveitis diagnosed prevalent cases in the US was around 378,281 in 2022.
• The US contributed to the largest Uveitis diagnosed prevalent population, acquiring ~37.5% of the 7MM in 2022. Whereas Spain accounted for the least, with around ~7% of the total population share, respectively, in 2022.
• In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, there were nearly 344,587 cases of NIU, while IU accounted for around 33,695 cases. These numbers are expected to rise during the forecast period due to the rise of overall uveitis infection in the US.
• According to DelveInsight estimates, in EU4 and the UK, based on anatomical location highest cases of uveitis were diagnosed in anterior uveitis, while intermediate uveitis has the least cases. In EU4 and the UK, anterior uveitis accounted for approximately 203,439, followed by 84,154 cases in posterior uveitis, 81,773 cases in pan uveitis, and 46,485 in intermediate uveitis in 2022, which are projected to increase during the forecast period.
• Japan accounted for approximately 214,892 diagnosed prevalent cases of uveitis, out of which nearly 8,039 cases were of HLA-B27-associated uveitis, 17,315 sarcoidosis, 9,894 Behçet's disease, 8,658 Vogt-Koyanagi-Harada disease, 618 JIA, 309 ankylosing spondylitis, 3,092 tuberculosis, 11,749 herpes, 81,628 idiopathic, and 73,589 others cases in 2022. These uveitis cases are expected to change during the forecast period in Japan (2023-2034).
• Leading Uveitis companies working in the market are Tarsier Pharma, Oculis Pharma, Roche, Eli Lilly and Company, Acelyrin, Affibody Medical, Eyevensys, Priovant Therapeutics, Santen Inc, Aerie Pharmaceuticals, Allergan, Bausch Health, Merck, Pfizer Inc, Fera Pharmaceuticals, Teva Pharmaceutical Industries, EyePoint Pharmaceuticals, Amorphex Therapeutics Holdings, Astellas Pharma Inc, Bayer AG, Novartis, and others.
• As per DelveInsight analysis, in 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM.
• The total number of Uveitis diagnosed prevalent cases in the US was around 378,281 in 2022.
• Emerging Uveitis therapies such as TRS01, OCS-02, and RG6179 can potentially create a positive shift in the uveitis market size.

On Dec. 02, 2025, ANI Pharmaceuticals, Inc. (“ANI” or the“Company”) (Nasdaq: ANIP) today announced that it has established The FutureVision Advisory Council to help guide the strategic advancement of its ophthalmology and retina franchise within the Company's Rare Disease business. This steering committee includes seven retina specialists and three uveitis specialists recognized globally as leaders in their respective fields.

Uveitis Overview

Uveitis is an inflammatory condition affecting the uveal tract of the eye, which includes the iris, ciliary body, and choroid. It can be caused by infections, autoimmune disorders, trauma, or remain idiopathic. Symptoms include eye pain, redness, blurred vision, light sensitivity, and floaters, and severe cases can lead to vision loss if untreated. Uveitis is classified into anterior, intermediate, posterior, and panuveitis based on the affected region. Diagnosis relies on clinical evaluation, imaging, and laboratory tests. Treatment typically involves corticosteroids, immunosuppressants, and biologics, while emerging therapies aim to reduce side effects and improve long-term disease control.